Cytopoint
lokivetmab
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Cytopoint.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Cytopoint.
For practical information about using Cytopoint, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Cytopoint
|
Agency product number |
EMEA/V/C/003939
|
Active substance |
lokivetmab
|
International non-proprietary name (INN) or common name |
lokivetmab
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QD11AH91
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
4
|
Date of issue of marketing authorisation valid throughout the European Union |
25/04/2017
|
Contact address |
Product information
21/06/2019 Cytopoint - EMEA/V/C/003939 - IB/0007
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
-
Other dermatological preparations
-
Agents for dermatitis, excluding corticosteroids
Therapeutic indication
Treatment of clinical manifestations of atopic dermatitis in dogs.